Demographics, comorbidities (hypertension, diabetes, chronic kidney disease), hemodynamic parameters (SBP, cardiac index), metabolic markers (serum creatinine, lactate, ALT), treatment intensity (vasopressors, inotropes, mechanical circulatory support), and clinical trajectory (SCAI shock stage progression). This evidence concerns the gene GPT and chronic kidney disease.